Sanofi S.A.
Pharmaceuticals and BiotechnologyFounded 2004- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Sanofi S.A.
Company History
Founded 2004 in Paris, France
Last reviewed: 2025-07-15 · By Swet Parvadiya
The original Sanofi was founded in 1973 as a subsidiary of Elf Aquitaine — the French petroleum company — reflecting the era's logic that large industrial conglomerates should own pharmaceutical operations. The Clin-Midy acquisition in 1980 expanded the R&D capability that would eventually produce commercially significant drugs. The Sterling Winthrop acquisition in 1994 provided the US market access and established Sanofi's first significant American commercial infrastructure.
The 1999 merger creating Sanofi-Synthélabo was the consolidation move that built the scale required to compete with European pharmaceutical giants. The 2004 hostile takeover of Aventis — a company that was itself the product of the Hoechst-Rhône-Poulenc merger — created Sanofi-Aventis and immediately made the combined entity one of the five largest pharmaceutical companies in the world. The hostile nature of the takeover reflected both the strategic urgency and the difficulty of assembling pharmaceutical scale in the European market through negotiated deals.
The 2007 collaboration agreement with Regeneron, a then-smaller Tarrytown biotechnology company, was the investment that produced Dupixent a decade later. Sanofi records global Dupixent sales and shares profits with Regeneron under a structure where development costs are split 80 percent Sanofi and 20 percent Regeneron after the first positive Phase 3 results — an arrangement that remains in force as the drug has grown to $14.3 billion in annual sales and counting. Genzyme was acquired in 2011 for approximately $20 billion, adding the rare disease franchise that now represents one of Sanofi's most strategically differentiated capabilities.
Jean-François Dehecq (born 1940) is a French business executive who served as CEO of Sanofi from its founding in 1973 through the 2004 merger with Aventis. Trained as a pharmacist, Dehecq joined Elf Aquitaine before establishing Sanofi as a healthcare diversification vehicle. He led the company's expansion through serial acquisitions including Labaz, Clin-Midy, and Sterling Winthrop, building the foundation for Sanofi-Synthélabo's 1999 formation. His tenure culminated in the hostile takeover of Aventis, creating Sanofi-Aventis as Europe's largest pharmaceutical company. Dehecq retired in 2007, leaving a legacy of strategic M&A and European pharmaceutical consolidation.
René Sautier is a French business executive who co-founded Sanofi in 1973 as a subsidiary of Elf Aquitaine. Serving as Chairman alongside Jean-François Dehecq's Managing Director role, Sautier established the governance and financial frameworks that enabled Sanofi's early growth through acquisition. His oversight of the company's capital allocation and board structure provided the stability necessary for Sanofi to integrate multiple French pharmaceutical laboratories and build toward its eventual position as a global healthcare leader.
Sanofi was founded on December 20, 1973, as a subsidiary of French state-owned oil company Elf Aquitaine, with Jean-François Dehecq and René Sautier establishing the company to diversify into recession-resistant healthcare. The initial business model was a 'buy and build' acquisition vehicle financed entirely by Elf's capital reserves, with the first major acquisition of Labaz providing initial product lines and R&D capabilities.
Sanofi acquired the Clin-Midy group, significantly expanding its research and development capabilities and therapeutic breadth. This acquisition provided critical mass in pharmaceutical research and established the foundation for Sanofi's future pipeline development.
Sanofi acquired Sterling Winthrop's prescription drug business, establishing critical presence in the United States market. This transaction provided the transatlantic commercial footprint that would prove essential for future growth and positioned Sanofi as a global rather than European pharmaceutical company.
Sanofi merged with Synthélabo—a French pharmaceutical company with roots dating to 1970 and majority-owned by L'Oréal—to form Sanofi-Synthélabo. The merger consolidated French pharmaceutical research and commercial strengths, creating a company with sufficient scale to compete globally against US and Swiss giants. Elf Aquitaine and L'Oréal retained significant stakes in the new entity.
Sanofi-Synthélabo completed a $59.4 billion hostile takeover of larger domestic rival Aventis, creating Sanofi-Aventis as one of Europe's largest pharmaceutical companies. The bid was prompted by a proposed Novartis offer for Aventis and supported by the French government to maintain national pharmaceutical leadership. The merger integrated Aventis's diabetes (Lantus), oncology (Taxotere), and vaccines (Aventis Pasteur) franchises.
Sanofi-Aventis acquired Genzyme Corporation for approximately $20.1 billion in cash plus contingent value rights, transforming the company's strategic focus toward rare diseases and biotechnology. Genzyme's enzyme replacement therapies—Fabrazyme for Fabry, Cerezyme for Gaucher, and Myozyme for Pompe—became cornerstone products, while the acquisition established Sanofi as a global leader in rare diseases and provided manufacturing expertise in complex biologics.
Sanofi Pasteur's Dengvaxia received its first marketing authorization, becoming the world's first approved dengue vaccine after 20 years of development and approximately $1.8 billion in investment. The Philippines became the first country to launch a mass immunization program, administering the vaccine to over 800,000 schoolchildren.
Sanofi acquired Bioverativ for approximately $11.6 billion and Ablynx for approximately $4.8 billion, significantly strengthening its hematology and rare blood disorder franchises. Bioverativ added hemophilia therapies Eloctate and Alprolix, while Ablynx brought Nanobody technology and caplacizumab for acquired thrombotic thrombocytopenic purpura.
Sanofi announced updated Dengvaxia labeling restricting use to individuals previously exposed to dengue virus, after analysis showed the vaccine could increase severe dengue risk in seronegative individuals. The Philippines suspended its mass immunization program, leading to criminal investigations, license revocation in 2019, and lasting vaccine hesitancy that contributed to subsequent measles outbreaks.
Paul Hudson, previously at AstraZeneca, was appointed CEO of Sanofi, launching the 'Play to Win' strategic framework that prioritized immunology, rare diseases, and vaccines while planning the separation of non-core businesses. The strategy emphasized pipeline-driven growth, operational excellence, and portfolio transformation toward high-margin biopharmaceuticals.
Beyfortus (nirsevimab) received FDA approval for RSV prevention in infants, representing a breakthrough in passive immunization. The monoclonal antibody achieved blockbuster status in its first full year of sales in 2024, generating $1.9 billion and demonstrating Sanofi's ability to launch innovative vaccines.
Dupixent (dupilumab) generated $14.3 billion in FY2024 sales, up 23.1% year-over-year, exceeding management's target of approximately $14 billion. The drug became the eighth approved indication with COPD, treating over one million patients globally and establishing itself as one of the world's largest pharmaceutical products by revenue.
Sanofi announced its intention to sell a controlling stake in Opella consumer healthcare at an attractive valuation, with closing expected in Q2 2025. The separation will transform Sanofi into a focused, science-driven biopharmaceutical company, improving operating margins toward 32% while removing $4.9 billion in lower-margin consumer revenue.
Sanofi announced a record $1.4 billion investment to expand biologics manufacturing capacity in France, supporting industrial-scale production of monoclonal antibodies including Dupixent and pipeline assets. This represents the largest single manufacturing capital commitment in company history.
Sanofi completed the acquisition of Blueprint Medicines for approximately $9.5 billion, adding precision oncology assets including Ayvakit (avapritinib) for GIST and Gavreto (pralsetinib) for RET-altered cancers. This transaction, combined with the $1.5 billion Vicebio acquisition and $1.9 billion Dren Bio acquisition, represented more than $13 billion in 2025 business development activity.
Sanofi acquired Genzyme to pivot from a diversified pharmaceutical company toward rare diseases and biotechnology. Genzyme was the global leader in enzyme replacement therapies for lysosomal storage diseases, with established products including Fabrazyme, Cerezyme, and Myozyme. The acquisition provided manufacturing expertise in complex biologics, a rare disease commercial infrastructure, and a pipeline of orphan drug candidates.
Sanofi acquired Bioverativ to strengthen its hematology franchise, particularly in hemophilia. Bioverativ had been spun off from Biogen and owned Eloctate (hemophilia A) and Alprolix (hemophilia B), two extended half-life clotting factor therapies. The acquisition complemented Genzyme's rare disease portfolio and provided expertise in blood disorder commercialization.
Sanofi acquired Ablynx for its Nanobody technology platform and caplacizumab, a Nanobody for acquired thrombotic thrombocytopenic purpura (aTTP). Nanobodies are single-domain antibody fragments derived from camelid heavy-chain antibodies, offering potential advantages in tissue penetration and manufacturing.
Sanofi acquired Blueprint Medicines to accelerate its oncology presence, particularly in precision medicine. Blueprint's portfolio includes Ayvakit (avapritinib) for GIST and Gavreto (pralsetinib) for RET-altered cancers, along with a pipeline of targeted therapies. The acquisition represented Sanofi's largest transaction since Genzyme and signaled management's urgency to diversify beyond Dupixent.
Sanofi acquired Dren Bio for its bispecific antibody platform, which enables targeted depletion of pathogenic cells and proteins. The technology has applications in immunology, oncology, and infectious diseases, complementing Sanofi's existing antibody capabilities.
Sanofi acquired Vigil Neuroscience to add neuroscience assets, including a TREM2-targeting therapy for Alzheimer's disease and other neurodegenerative conditions. The acquisition reflects Sanofi's interest in building a neuroscience presence after previous setbacks in the therapeutic area.
Sanofi traces its origin to 1973, when French oil major Elf Aquitaine created a pharmaceutical subsidiary by combining several small French drug companies it had acquired during its 1970s diversification push. The subsidiary was named Sanofi, derived from the Greek roots sano, meaning healthy, and phi, a play on the Greek philosophos. Sanofi's first chairman was Jean-François Dehecq, an Elf executive who would lead the company through decades of acquisitions and rebrands. The Sanofi structure that anchors today's company emerged through a sequence of mergers: a 1999 combination with Synthelabo, the pharmaceutical division of L'Oreal, created Sanofi-Synthelabo, listed on the Paris Bourse and immediately the second-largest French pharmaceutical company after Aventis. In August 2004, Sanofi-Synthelabo acquired Aventis in a hostile and contested $65 billion transaction, forming Sanofi-Aventis. Aventis itself was the product of the 1999 merger of Hoechst of Germany and Rhone-Poulenc of France, both with century-long pharmaceutical histories of their own. The combined entity was renamed simply Sanofi in May 2011 under chief executive Chris Viehbacher to retire the hyphenated brand. The current Sanofi is therefore the product of one of the largest pharmaceutical consolidations in European history.
The Sanofi-Aventis merger, completed in August 2004 for roughly 55 billion euros or $65 billion at the time, created the third-largest pharmaceutical company in the world by revenue and the largest in Europe. The transaction was structured as a hostile takeover bid by Sanofi-Synthelabo, the considerably smaller French pharmaceutical group, for Aventis, the larger and more international Franco-German champion formed in 1999 from the merger of Hoechst and Rhone-Poulenc. The deal was politically charged: Aventis initially resisted, sought a friendly merger with Swiss giant Novartis, and was blocked from doing so by French prime minister Jean-Pierre Raffarin and President Jacques Chirac, who declared the asset a national strategic priority. Sanofi-Synthelabo prevailed by raising its bid and securing French government support. The combined company gained the international scale that French pharmaceuticals had long lacked, plus blockbuster franchises in cardiovascular drugs including Plavix, sleep disorders, vaccines through Sanofi Pasteur, and oncology. Integration was prolonged and disruptive, and the 2011 rebrand to simply Sanofi marked the end of the post-merger transition. The deal also entrenched France's dirigiste approach to pharmaceutical industrial policy and set the precedent that subsequent CEOs would navigate with French government stakeholders.
Sanofi built its rare disease franchise primarily through the $20.1 billion acquisition of Genzyme, announced February 16, 2011 and closed April 1, 2011, at the time the largest pharmaceutical acquisition by a European company in more than five years. Genzyme, founded in Boston in 1981, was the pioneer of enzyme replacement therapy for ultra-rare metabolic diseases including Gaucher disease via Cerezyme, Fabry disease via Fabrazyme, mucopolysaccharidosis I via Aldurazyme, and Pompe disease via Myozyme and Lumizyme, plus multiple sclerosis drug Aubagio and the renal portfolio. The deal closed after a protracted public negotiation in which Genzyme CEO Henri Termeer rejected multiple bids before agreeing at $74 per share plus contingent value rights tied to Lemtrada multiple sclerosis sales. Sanofi reinforced rare diseases with the November 2018 acquisition of Bioverativ, the hemophilia spin-out of Biogen, for $11.6 billion or $105 per share, gaining hemophilia A drug Eloctate and hemophilia B drug Alprolix. The 2018 acquisition of Belgian nanobody specialist Ablynx for $4.8 billion added Cablivi for acquired thrombotic thrombocytopenic purpura. Genzyme and Bioverativ revenues are reported within Sanofi's Specialty Care segment, which now exceeds 15 billion euros annually.
Sanofi Pasteur, the vaccines division, is among the oldest and largest vaccine producers in the world, tracing its roots to the 1897 founding of Institut Merieux in Lyon, France by Marcel Merieux, a former assistant to Louis Pasteur. The Merieux Institute became a global vaccine power through the 20th century, was acquired by Rhone-Poulenc in 1968, and merged with Hoechst's Pasteur vaccines business under Aventis, which Sanofi acquired in 2004. Sanofi Pasteur today operates one of the broadest vaccine portfolios in the industry, with products for influenza, polio, diphtheria, tetanus, pertussis, meningococcal disease, rabies, yellow fever, and dengue via Dengvaxia. The Beyfortus monoclonal antibody for respiratory syncytial virus prevention in infants, co-developed with AstraZeneca and launched in 2023, became a significant commercial success in its first full year, generating roughly 1.7 billion euros in 2024. Vaccines revenue overall was approximately 7.4 billion euros in 2024, making Sanofi the second-largest vaccine producer globally after Merck and ahead of Pfizer for non-COVID vaccines. The business has manufacturing operations in France, Pennsylvania, Singapore, and several emerging markets, and is the largest supplier of influenza vaccines globally.
Sanofi has executed a sequence of portfolio moves between 2019 and 2024 to focus the company on innovative medicines and exit lower-growth diversified businesses. The 2019 appointment of Paul Hudson as chief executive accelerated the shift. The chemistry business was spun off as Euroapi via a Paris listing in May 2022, with Sanofi retaining a minority stake that has since been reduced. The largest single move was the 2024 separation of the consumer healthcare business, branded Opella, which includes Allegra, Doliprane, Buscopan, Mucosolvan, Magne B6, and Aspegic, plus Dulcolax and Zantac in some markets. In October 2024, Sanofi announced the sale of a 50 percent controlling stake in Opella to US private equity firm Clayton Dubilier and Rice, valuing the consumer healthcare business at approximately 16 billion euros enterprise value and generating an estimated 13.6 billion euros in cash proceeds for Sanofi after debt and minority interests. The transaction closed in 2025. Sanofi also divested non-core diabetes assets, sold its US prescription Zantac liability exposure, and exited certain established products. Remaining Sanofi is anchored by Dupixent, the vaccines business, rare diseases, and an immunology-focused R and D pipeline.